Dr Reddy’s Laboratories Ltd (DRL) is an integrated global pharmaceutical company committed to providing affordable and innovative medicines for healthier lives.
Through its three businesses – Pharmaceutical Services &Active Ingredients Global Generics and Proprietary Products – Dr. Reddy’s offers a portfolio of products and services including Active Pharmaceutical Ingredients (APIs) custom pharmaceutical services generics biosimilars and differentiated formulations. The company’s major therapeutic areas of focus are gastrointestinal cardiovascular diabetology oncology pain management and dermatology. Dr. Reddy’s operates in markets across the globe. Its major markets include – USA India Russia & CIS countries and Europe.Dr Reddy’s Laboratories was incorporated in the year 1984 in Hyderabad. The company was established by Dr Anji Reddy with an initial capital outlay of Rs 25 lakh.
The company made their beginning with the manufacture of Active Pharmaceutical Ingredients and Intermediates (API) and commenced operations with a single drug in a 60-tonne facility near Hyderabad India. In the year 1986 the company shares were listed on the Bombay Stock Exchange. Also they entered international market with exports of Methyldopa.In the year 1987 the company obtained first USFDA approval for Ibuprofen API. In the year 1988 they acquired Benzex Laboratories Pvt Ltd to expand their Bulk Actives business. In the year 1990 they exported Norfloxacin and Ciprofloxacin to Europe and Far East. In the year 1991 they commenced formulation exports to Russia.In the year 1993 the company established Dr. Reddy’s Research Foundation and initiated drug discovery programme. In the year 1994 they finished dosages facility established to cater to highly regulated markets such as the US. In the year 1995 the company set up joint venture in Russia. In the year 1997 they filled first ANDA with the United States Food and Drug Administration for Ranitidine. In the year 1999 the company acquired American Remedies Ltd a pharmaceutical company based in India. In the year 2000 Cheminor Drugs Ltd a group company merged with the company and thus the company became India’s third largest pharma company.
In the year 2001 the company launched Fluoxetine capsules. They became the first Indian company to win 180-day exclusivity for a generic drug in the US. Also they launched their first generic product Ranitidine in the US market.In the year 2002 the company made their first overseas acquisition of BMS Laboratories Limited and Meridian Healthcare in UK. In the year 2003 they launched Ibuprofen first generic product to be marketed under the ‘Dr. Reddy’s’ label in the US. In the year 2005 they acquired Roche’s API Business at its manufacturing site in Mexico. In the year 2006 the company acquired Betapharm the fourth largest generics company in Germany for a total enterprise value of Rs 480 million. In the year 2007 the company launched Reditux – the world’s first biosimilar MAb – for the treatment of Non Hodgkins Lymphoma.
No comments:
Post a Comment